Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium

Por Beeh, Kai-Michael, Beier, Jutta, Donohue, James F
Publicado em 2012

Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype – a post-hoc analysis of a randomized, double-blind, placebo-controlled clinic...

Por Beeh, Kai-Michael, Beier, Jutta, Candler, Henning, Wittig, Thomas
Publicado no Int J Chron Obstruct Pulmon Dis (2016)

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe pers...

Por Beeh, Kai-Michael, LaForce, Craig, Gahlemann, Martina, Wenz, Arne, Toorawa, Robert, Fležar, Matjaž
Publicado no Respir Res (2015)

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

Por Beeh, Kai-Michael, Moroni-Zentgraf, Petra, Ablinger, Othmar, Hollaenderova, Zuzana, Unseld, Anna, Engel, Michael, Korn, Stephanie
Publicado em 2014

The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGIT...

Por Beeh, Kai-Michael, Derom, Eric, Echave-Sustaeta, José, Grönke, Lars, Hamilton, Alan, Zhai, Dongmei, Bjermer, Leif
Publicado no Int J Chron Obstruct Pulmon Dis (2016)

Tolerability and pharmacokinetics of inhaled bimosiamose disodium in healthy males

Por Meyer, Michael, Beeh, Kai-Michael, Beier, Jutta, Beyer, Diana, Aydt, Ewald, Zahlten, Rainer, Jilma, Bernd, Wolff, Gerhard
Publicado em 2007

Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations

Por Beeh, Kai-Michael, Hederer, Bettina, Glaab, Thomas, Müller, Achim, Moelken, Maureen Rutten-van, Kesten, Steven, Vogelmeier, Claus
Publicado em 2009

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat(®) in Asthma Using Standardized Sample-Contamination Avoidance

Por Beeh, Kai-Michael, Kirsten, Anne-Marie, Dusser, Daniel, Sharma, Ashish, Cornelissen, Piet, Sigmund, Ralf, Moroni-Zentgraf, Petra, Dahl, Ronald
Publicado no J Aerosol Med Pulm Drug Deliv (2016)

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β(2)-agonist, in patients with asthma: results of a parallel-group study and a crossover study

Por O’Byrne, Paul M., D’Urzo, Tony, Beck, Ekkehard, Fležar, Matjaž, Gahlemann, Martina, Hart, Lorna, Blahova, Zuzana, Toorawa, Robert, Beeh, Kai-Michael
Publicado no Respir Res (2015)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

Por Chapman, Kenneth R, Beeh, Kai-Michael, Beier, Jutta, Bateman, Eric D, D’Urzo, Anthony, Nutbrown, Robert, Henley, Michelle, Chen, Hungta, Overend, Tim, D’Andrea, Peter
Publicado em 2014

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis

Por Di Marco, Fabiano, Sotgiu, Giovanni, Santus, Pierachille, O’Donnell, Denis E., Beeh, Kai-Michael, Dore, Simone, Roggi, Maria Adelaide, Giuliani, Lisa, Blasi, Francesco, Centanni, Stefano
Publicado no Respir Res (2018)

Correction to: Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis

Por Di Marco, Fabiano, Sotgiu, Giovanni, Santus, Pierachille, O’Donnell, Denis E., Beeh, Kai-Michael, Dore, Simone, Roggi, Maria Adelaide, Giuliani, Lisa, Blasi, Francesco, Centanni, Stefano
Publicado no Respir Res (2018)